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Abstract 
Caveolin-1 plays a complex role in prostate cancer and has been suggested to be a potential 
biomarker and therapeutic target. Since mature caveolin-1 resides in caveolae, invaginated lipid 
raft domains at the plasma membrane, caveolae have been suggested as a tumor-promoting 
signaling platform in prostate cancer. However, caveola formation requires both caveolin-1 and 
cavin-1 (also known as PTRF; polymerase I and transcript release factor). Here, we examined the 
expression of cavin-1 in prostate epithelia and stroma using tissue microarray including normal, 
non-malignant and malignant prostate tissues. We found that caveolin-1 was induced without the 
presence of cavin-1 in advanced prostate carcinoma, an expression pattern mirrored in the PC-3 
cell line. In contrast, normal prostate epithelia expressed neither caveolin-1 nor cavin-1, while 
prostate stroma highly expressed both caveolin-1 and cavin-1. Utilizing PC-3 cells as a suitable 
model for caveolin-1-positive advanced prostate cancer, we found that cavin-1 expression in PC-
3 cells inhibits anchorage-independent growth, and reduces in vivo tumor growth and metastasis 
in an orthotopic prostate cancer xenograft mouse model. The expression of α-smooth muscle 
actin in stroma along with IL-6 in cancer cells was also decreased in tumors of mice bearing PC-
3-cavin-1 tumor cells. To determine whether cavin-1 acts by neutralizing caveolin-1, we 
expressed cavin-1 in caveolin-1 negative prostate cancer LNCaP and 22Rv1 cells. Caveolin-1 
but not cavin-1 expression increased anchorage-independent growth in LNCaP and 22Rv1 cells. 
Cavin-1 co-expression reversed caveolin-1 effects in caveolin-1 positive LNCaP cells. Taken 
together, these results suggest that caveolin-1 in advanced prostate cancer is present outside of 
caveolae, due to the lack of cavin-1 expression. Cavin-1 expression attenuates the effects of non-
caveolar caveolin-1 microdomains partly via reduced IL-6 microenvironmental function. With 
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circulating caveolin-1 as a potential biomarker for advanced prostate cancer, identification of the 
molecular pathways affected by cavin-1 could provide novel therapeutic targets. 
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Introduction 
Caveolin-1 expression mediates the progression through the castration-resistant phase of prostate 
cancer by promoting Akt-mediated cell survival,1 enhancing androgen-regulated cell cycle 
progression,2 and via paracrine actions of secreted caveolin-1.3,4 Due to its bioactive circulating 
form, caveolin-1 has been suggested as a clinically relevant biomarker for high grade prostate 
cancer5 and disease recurrence.4,6 Furthermore, anti-caveolin-1 antibodies to neutralize 
circulating caveolin-1 have been suggested as potential therapy in prostate cancer.7 
Since caveolin-1 is an essential structural component of plasma membrane caveolae, cholesterol-
rich-invaginated pits at the plasma membrane,8 it has been assumed that caveolin-1 in prostate 
cancer cells forms caveolae. However, we recently demonstrated that the caveolin-1-positive 
prostate cancer cell line PC-3 lacks caveolae due to the absence of an essential co-factor cavin-1 
(also known as PTRF; polymerase I and transcript release factor).9 Caveolin-1 in PC-3 cells 
reside on flat plasma membrane as visualized by electron microscopy, but exhibits the same 
detergent-resistant property as caveolae, reflecting its partition to cholesterol-rich lipid raft 
membrane microdomains.9 To distinguish the planar lipid raft structural organization from 
caveolae, we term such tumor-promoting caveolin-1 conformation non-caveolar caveolin-1. 
Ectopic expression of cavin-1 in PC-3 cells stabilizes the caveolin-1 protein and induces caveola 
formation,9 concomitant with reduction in cellular migration.10,11 Our cellular and proteomics 
studies revealed a potential molecular mechanism in that cavin-1-induced cholesterol re-
distribution and reduction in the secretion of a subset of oncogenesis-related proteins such as 
proteases and cytokines.12 These results suggest distinct roles of caveolin-1 and cavin-1 in 
prostate cancer cells. 
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To date, only one study examined the expression of cavin-1 in prostate cancer, with the finding 
that cavin-1 is reduced or absent in prostate cancer tissues (n=21) but showed positive 
immunoreactivity in benign prostatic hyperplasia (BPH; n=17).13 Hence the current study sought 
to clarify the relative expression of caveolin-1 and cavin-1 in normal, non- and malignant patient 
tissues, and to determine relative roles of caveolae versus non-caveolar caveolin-1 
microdomains, by modulating cavin-1 co-expression in prostate cancer cells. 
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Results 
Expression of caveolin-1 and cavin-1 in prostate tissues 
We generated a rabbit polyclonal antibody against the N-terminal 15 amino acids of human 
cavin-1. Following affinity-purification against the antigenic peptide, the specificity of the 
antibody was confirmed by immunoblotting with lysates from several previously characterized 
cell lines in Hill et al.9 To investigate the expression of caveolin-1 and cavin-1 in prostate 
tissues, we performed immunohistochemistry (IHC) on two tissue microarrays (TMA) from the 
Australian Prostate Cancer BioResource. The normal prostate tissue array was designed to show 
age-related histological changes, and contained 2 to 3 cores from 141 prostate cancer-free 
participants with age range from 15 to 79 (mean 37.5). The Gleason graded tissue microarray 
contained cores from 117 patients with Gleason scores 4-9 with matching non-malignant tissue 
(adjacent normal and benign prostatic hyperplasia; BPH). The mean patient age for the Gleason 
grade TMA was 63 (range 52 - 74). Semi-quantitative assessment of the immunostaining for 
caveolin-1 and cavin-1 was performed independently by two pathologists (C Soon Lee and 
Sowmya Sharma) using a scoring system, where a score of 2 indicates strong staining in more 
than 30% of tissue, a score of 1 indicates diffuse staining or strong staining in less than 30% of 
tissue, and score 0 indicates no staining. Interobserver variation was seen in less than 1% of the 
cases (14 of the tissue cores) and any discrepant results were reassessed by both pathologists 
simultaneously at a multiheader microscope and a consensus result was then obtained. As the 
loss of caveolin-1 in prostate stroma has been proposed as a marker of metastatic progression,14 
the stroma compartment (Table 2) was scored separately from the epithelia/carcinoma (Table 1). 
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Consensus scores were categorized in contingency tables, with scores 1 and 2 categorized as 
‘positive’ and score 0 as ‘negative’. 
In total, 258 participants were assessed for caveolin-1 and cavin-1 expression. The previously 
reported up-regulation of caveolin-1 in advanced prostate carcinoma15-17 was replicated in our 
study cohort (Figure 1a and Table 1; p<0.0001). Endothelial cells of blood vessels served as 
internal positive controls, having high expression of caveolin-1 and cavin-1 (Figure 1; black 
arrow head). Analysis of the TMA results showed a lack of cavin-1 expression in normal as well 
as malignant prostate epithelia (Figure 1b and Table 1), indicating that caveolin-1 in prostate 
cancer (epithelial compartment) is present in non-caveolar microdomains. On the other hand, 
normal prostate stroma highly expressed both caveolin-1 and cavin-1 which was significantly 
reduced in malignant stroma (Table 2; p<0.0001). The loss of stromal caveolin-1 and cavin-1 
expression significantly correlated with Gleason score (Table 2; p<0.0001). Loss of stromal 
caveolin-1 has been correlated with elevated prostate cancer caveolin-1,14 therefore we went on 
to examine the correlation between epithelial caveolin-1 and stroma cavin-1. Caveolin-1 is most 
prevalent in the high risk (Gleason score ≥ 8) group, with 75% of the patients showing positivity 
(Table 1). In this group, stromal caveolin-1 and cavin-1 was lost in 35% and 53% respectively, 
suggesting that epithelial caveolin-1 expression leads to loss of stromal caveolin-1 and cavin-1 
(and loss of caveolae structure). This is in agreement with the observation for stromal caveolin-1 
by Di Vizio et al.14 However, a direct causal relationship remains to be confirmed. In the current 
study, we focused on the tumor-promoting actions of non-caveolar caveolin-1 and modulation by 
cavin-1. 
Cavin-1 co-expression suppressed PC-3 tumor progression and metastasis 
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To identify and generate suitable cell models for investigation of non-caveolar caveolin-1, we 
examined the caveolin-1 and cavin-1 expression pattern in three commonly-used prostate cancer 
cell lines, LNCaP, 22Rv1 and PC-3. Similar to the TMA results, all three cell lines lacked cavin-
1 expression (Figure 2a). In contrast, caveolin-1 was detected in PC-3 cells, but not in LNCaP or 
22Rv1 cells (Figure 2a). Previously we reported that cavin-1 co-expression with caveolin-1 
induced caveolae in PC-3 cells,9 concomitant with reduced migration and membrane 
protrusion.10,11 Here, we further show that cavin-1 over-expression significantly decreased cell 
growth and anchorage-independent growth of PC-3 cells (Figure 2b and c). In order to confirm 
these in vitro findings in an in vivo mouse model, we utilized a previously reported PC-3 
luciferase cell line18 and generated independent cell lines stably expressing cavin-1 or vector 
control (Supplementary Figure S1a). As the lentivirus expresses GFP under a bi-cistronic 
promoter, we used flow cytometry to isolate 99%-pure population of expressing cells. Cell 
proliferation and anchorage-independent growth were measured, and the PC-3 luciferase cell 
lines were confirmed to behave similarly to the original PC-3 cell lines (Supplementary Figure 
S1b). Prior to use in an orthotopic prostate cancer xenograft mouse model, we confirmed that the 
two cell lines showed similar linear intensities of in vitro bioluminescence correlating with cell 
number (Supplementary Figure S2). Half a million PC-3 cells were injected into dorsolateral 
prostate glands of NOD/SCID mice. Tumor progression and metastases were examined by in 
vivo and ex vivo bioluminescence imaging. PC-3-cavin-1 cells showed a significant reduction in 
tumor progression compared to control PC-3 cells (Figure 3a and b), and smaller size and weight 
of prostate tumors were confirmed by necropsy at the end of experiments (Figure 3c and d; 
p=0.0007). Ex vivo bioluminescence imaging also revealed a significant reduction (15.2 fold 
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reduction; p=0.0289) of lung metastases in mice injected with PC-3-cavin-1 cells compared with 
PC-3 control (Figure 3e). 
Cavin-1 co-expression reduced IL-6 and α-SMA in prostate tumor and stroma in PC-3 
xenografts 
To determine in vivo tumor cell proliferation, formalin-fixed paraffin-embedded sections were 
stained for Ki-67 (Figure 4a). The number of Ki-67 positive cells was quantified by two 
researchers independently counting cells at 5 different high power fields per sample (Figure 4b). 
In agreement with the in vivo bioluminescence results, PC-3-cavin-1 tumor showed significantly 
reduced in vivo proliferation (Figure 4a and b; p=0.0001). Next we examined the tumor tissues 
for IL-6 levels as a potential molecular mediator of the tumor suppressing effect of cavin-1. 
Our previous study using quantitative proteomics revealed that cavin-1 co-expression on PC-3 
cells reduced the secretion of growth factors and proinflammatory cytokines including 
interleukin-6 (IL-6).12 IL-6 has been implicated in prostate cancer progression,19 particularly 
with gaining androgen-independence.20,21 Furthermore, anti-IL-6 monoclonal antibody has 
demonstrated effectiveness against castration-resistant prostate cancer (CRPC).21-23 Since 
caveolin-1 is associated with androgen-insensitivity,24 attenuation of IL-6 may be a potential 
mechanism of the anti-tumor effect of cavin-1 expression in our PC-3 prostate tumor model. 
Staining of primary prostate tumor tissues with anti-human IL-6 antibodies revealed significantly 
reduced IL-6 expressions in PC-3-cavin-1 tumors compared to control tumors (Figure 4c and d; 
p=0.0049). Recently, IL-6 has been proposed to mediate the establishment of the tumor 
microenvironment by reciprocal interplay between stroma and cancer cells.25-27 To examine if 
cavin-1 expression also affected the tumor microenvironment, we examined the expression of 
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alpha-smooth muscle actin (α-SMA) which is one of main activation markers for reactive 
stroma.28 As seen in Figure 4e and f, α-SMA was reduced in stromal tissues in mice bearing PC-
3-cavin-1 tumor cells (p=0.0014). These results suggest that cavin-1 expression attenuates PC-3 
tumor progression, possibly via the IL-6 pathway and cross-talk between cancer and stromal 
cells. 
Cavin-1 inhibits anchorage-independent growth in caveolin-1 positive LNCaP cells 
Caveolin-1 is associated with the development of androgen-independence.29 Our previous studies 
examined cavin-1 function in androgen-independent prostate cancer cells and suggest that cavin-
1 exerts both caveolin-1-dependent and -independent functions.10,11 To determine if the same 
holds in androgen-sensitive prostate cancer cells, which do not express caveolin-1 (Figure 2) we 
generated 22Rv1 and LNCaP cell lines stably expressing caveolin-1 or cavin-1 using the same 
lentivirus system as above, and confirmed their expression by western blotting (Figure 5a). Cell 
proliferation and anchorage-independent growth was measured for these cell lines. In contrast to 
the PC-3 cells (Figure 2b), neither caveolin-1 nor cavin-1 over-expression altered cell 
proliferation in 22Rv1 or LNCaP cells (Figure 5b and c). However, caveolin-1 over-expression 
significantly accelerated colony formation in soft agar in both cell lines, while cavin-1 had no 
effect on anchorage-independent growth (Figure 5d and e). These results suggest that cavin-1 
expression alone has no effect on tumor-promoting potential of caveolin-1 negative androgen-
dependent prostate cancer cells. 
Next we examined if cavin-1 co-expression could reverse caveolin-1-induced anchorage-
independent growth in LNCaP cells. Cavin-1 lentivirus was used to infect caveolin-1-expressing 
LNCaP cells. Expression levels were confirmed by immunoblotting (Figure 6a), and >95% of 
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cells expressed cavin-1 as confirmed by immunofluorescence with cavin-1 antibody (not shown). 
Confocal immunofluorescence using anti-caveolin-1 and cavin-1 antibodies showed co-
localization to surface puncta suggesting caveola formation and localization (Figure 6b). 
Consistent with Figure 5b and c, cavin-1 expression had no effect on cell proliferation of 
LNCaP-caveolin-1 cells (Figure 6c). In contrast, cavin-1 co-expression in caveolin-1 positive 
LNCaP cells significantly inhibited anchorage-independent growth (Figure 6d). This set of 
experiments indicates that cavin-1 can neutralize the tumor-promoting effects of non-caveolar 
caveolin-1 but does not itself alter tumor-promoting potential of prostate cancer cells. 
Cavin-1 co-expression neutralizes caveolin-1-mediated androgen receptor and IL-6 
expression, and Akt phosphorylation 
To further delineate the molecular pathways modulated by cavin-1, we examined three prostate 
cancer targets associated with caveolin-1, androgen receptor (AR),30 IL-6 (Figure 4c and d) and 
phospho-Akt1,31 using our LNCaP and PC-3 cell models. As shown in Figure 7a, caveolin-1 
overexpression increased cellular levels of AR (1.69 ± 0.09, p=0.0034) and IL-6 (1.89 ± 0.06, 
p=0.0066) in LNCaP cells, while cavin-1 overexpression showed no significant changes of AR 
(1.11 ± 0.08, p=0.4657) or IL-6 (1.32 ± 0.10, p=0.1424). In agreement with a planar caveolin-1-
neutralizing role, cavin-1 co-expression significantly decreased the expression of AR (1.15 ± 
0.11, p=0.0227) and IL-6 (1.17 ± 0.17, p=0.0086) in LNCaP-caveolin-1 cells (Figure 7a). 
Previously, we reported reduced secretion of IL-6 from PC-3 cells upon cavin-1 
overexpression.12 Therefore, we also examined if the secretion of IL-6 from LNCaP cells was 
changed by either caveolin-1 or cavin-1 overexpresison. As a positive control, caveolin-1 was 
detected in the conditioned media of caveolin-1 positive cells (Figure 7b) as previously 
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reported.3 The secretion of caveolin-1 in LNCaP (Figure 7b; 1.08 ± 0.14) and PC-322 was not 
significantly altered upon cavin-1 overexpression. Previous papers consistently reported the 
expression of receptors for IL-6 in LNCaP cells, however there have been conflicting results as 
to whether or not LNCaP cells secrete IL-6.32-34 In this study, we found that neither caveolin-1 
nor cavin-1 expression induced the secretion of IL-6 in LNCaP cells (Figure 7b), although 
cellular IL-6 levels were altered by overexpression of caveolin-1 or cavin-1 co-expression 
(Figure 7a). 
Caveolin-1 has been reported to regulate cell signaling via phosphatidylinosidie-3-kinase (PI3K)-
Akt and Ras-ERK pathways.35 To determine if cavin-1 expression alters caveolin-1-mediated 
cell signaling, we examined the level of pAkt and pERK in cell extracts from caveolin-1 positive 
LNCaP and PC-3 cells. As shown in Figure 7c, cavin-1 overexpression specifically reduced the 
levels of phosphorylated Akt in LNCaP-caveolin-1 (0.71 ± 0.04. p=0.0048) and PC-3 (0.68 ±0.1, 
p=0.0482) cells, without affecting ERK 1/2 phosphorylation. 
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Discussion 
Although caveolin-1 has been associated with aggressive prostate cancer since the 1990s, this is 
the first study to comprehensively demonstrate that caveolin-1 in the majority of prostate 
carcinoma is present in non-caveolar microdomains due to the lack of cavin-1 expression. We 
further show that cavin-1 expression attenuates PC-3 tumor progression in vivo, with 
microenvironmental modulation as a potential mechanism (Figure 8). The tumor-suppressing 
effect of cavin-1 is dependent on the presence of non-caveolar caveolin-1, since expression of 
cavin-1 alone in LNCaP and 22Rv1 cells (caveolin-1 negative) did not affect anchorage-
independent growth, but interfered with the tumor-promoting ability of planar caveolin-1. Cavin-
1 co-expression also reversed the caveolin-1-induced elevation of AR and IL-6 expression in 
LNCaP cells, and specifically reduced pAkt with modulating pERK in LNCaP and PC3 cells. 
Hence, investigating the molecular pathway modulated by cavin-1 will allow identification of 
novel therapeutic targets for caveolin-1-positive prostate cancer patients. Such a personalized 
treatment strategy is highly translatable to the clinic since circulating caveolin-1 is a ready 
minimally-invasive biomarker to identify these high risk patients.36 
Other cavin family members, cavin-2 (serum deprivation-response protein, SDPR), cavin-3 
(protein kinase C, delta binding protein, PRKCDBP, also known as SRBC), and cavin-4 
(muscle-restricted coiled-coil protein, MURC), also play important roles in caveola functions.37-
39 While few studies directly examine the role of cavin-2 and cavin-3 in cancer, several studies 
have identified down-regulation of cavin-2 or cavin-3 via methylation in different cancers, 
including prostate.40-43 These results are in agreement with our hypothesis of a tumor-promoting 
role for non-caveolar caveolin-1, either due to loss of caveolae structure as in the case of reduced 
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cavin-2 or cavin-3 expression, or due to aberrant expression of caveolin-1 in cells that do not 
express cavin-1, as in the case of PC3 cells (Figure 8). 
While cavin-1 is absent in normal, non-malignant and malignant prostate epithelia in our cohort 
(n=258 participants), Gould et al13 showed positive cavin-1 immunoreactivity in benign prostatic 
hyperplasia (BPH; n=17). Our cavin-1 immunohistochemistry quality was assured by the strong 
stromal cavin-1 staining and positivity of endothelial cells on the same slides. One possible 
explanation for the discrepancy is the different epitopes of the antibodies used. We generated a 
new polyclonal antibody to the N-terminal peptide of human cavin-1, while Gould et al13 used a 
commercial antibody generated using recombinant mouse cavin-1 protein comprising the middle 
region (amino acids 157-272). Hence there is the intriguing possibility that proteolytic cleavage 
may regulate cavin-1 levels in prostate epithelium. Cavin-1 contains PEST sequences and has 
been reported to be proteolytically cleaved in adipocyte caveolae.44 Whether cavin-1 cleavage 
occurs outside of caveolae, and its relevance in prostate cancer remains to be investigated. 
A role for stromal caveolin-1 in remodeling of the microenvironment has been proposed,45 
although the mechanism underlying the differential function of caveolin-1 in the cancer cell and 
the stroma is unclear. In terms of prostatic stroma, caveolin-1 and cavin-1 expression has been 
examined in the prostate stroma cell line, PrSC,13 and we also confirmed high expression of 
stromal caveolin-1 and cavin-1 in the TMA suggesting abundant caveolae in normal prostate 
stroma. Importantly, in contrast to the cancer cell where caveolin-1 is induced in advanced 
disease, loss of caveolin-1 expression in prostate cancer stroma correlates with prostate cancer 
progression and metastasis.14 Here we provide the first evidence that stromal cavin-1 is also 
reduced in prostate cancer, compared to all benign stroma include benign hyperplasia. The 
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concomitant reduction of stromal caveolin-1 and cavin-1 suggests down-regulation of stromal 
caveolae in prostate cancer. This is in stark contrast to the induction of non-caveolar caveolin-1 
in advanced prostate cancer cells. These complex roles of caveolin-1 and caveolae between 
prostate epithelia (pro-tumor) and stroma (anti-tumor) highlight the limitations and difficulties in 
the therapeutic approach to caveolin-1 in advanced prostate cancer. 
One of the most important targets in prostate cancer is the AR. Misregulated activation of AR 
has been associated with progression of advanced prostate cancer, and contributes to resistance 
to androgen deprivation therapy.46 Caveolin-1 expression has been correlated with androgen 
deprivation therapy and castration resistance.4,15 Proposed molecular mechanisms for caveolin-1 
in castration resistant prostate cancer include activation of the Akt pathway,1,31 and an increase in 
the activity of AR in a low androgen environment.46 Here we show that cavin-1 co-expression 
reversed planar caveolin-1-stimulated AR expression and specifically down-regulated pAkt 
without affecting pERK. Co-ordinated inhibition of PI3K and AR caused tumor regression,47 
hence further characterization of the molecular pathways activated by planar caveolin-1, and 
attenuated by cavin-1, may lead to novel therapeutic targets for caveolin-1-positive prostate 
cancer. 
Previously we showed attenuated secretion of IL-6 from cavin-1 expressing PC-3 cells.12 Here, 
we report that cavin-1 expression correlates with a significant reduction in IL-6 levels in PC-3 
xenograft tumors. Furthermore, using α-SMA as a marker for myofibroblasts, we found a 
significant reduction of reactive stroma in cavin-1-PC-3 tumors compared to control. IL-6 is a 
pleiotropic cytokine implicated in prostate cancer progression and a potential therapeutic 
target.21,23 IL-6 in the tumor microenvironment has been reported to trigger activation of reactive 
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stroma including fibroblasts and immune cells, also known as the efferent pathway (tumor cells 
stimulate mesenchymal-mesenchymal transition; MMT).25,26 Furthermore, IL-6 is involved in the 
afferent pathway, where reactive stroma activates epithelial-mesenchymal transition (EMT).26,27 
The study also showed that coinjection of IL-6-stimulated human prostate fibroblast with PC-3 
cells increased PC-3 in vivo tumor formation and lung metastases.25 While IL-6 functions as an 
autocrine growth factor for PC-3 cells, there have been conflicting results regarding IL-6 
secretion from LNCaP cells.32-34 In our study, IL-6 secretion was not detected in any of the 
LNCaP stable cell lines, but we found that LNCaP cells expressed IL-6 which was slightly but 
significantly increased by caveolin-1 expression. Expression of cavin-1 in LNCaP-caveolin-1 
cells reduced IL-6 expression. However, since IL-6 is not secreted from any of the LNCaP cell 
lines, the functional significance of IL-6 regulation by caveolin-1 and cavin-1 in LNCaP cells 
remains unclear. Recent phase II trials report partial therapeutic efficacy of CNTO328 
(siltuximab), anti-IL-6 monoclonal antibody, in castration-resistant prostate cancer.21,23 In 
previous studies, anti-IL-6 therapy using CNTO328  inhibited the conversion of androgen 
dependent to androgen independent phenotype of prostate cancer in a mouse model.21 Therefore, 
one possibility is that during the acquisition of androgen independence, prostate cancer cells 
acquire the ability to secretion IL-6. 
In summary, the data presented in this work demonstrate differential expressions of caveolin-1 
and cavin-1 in prostate carcinoma and stroma, and confirm a potential tumor-promoting role of 
non-caveolar caveolin-1 in advanced prostate cancer. Cavin-1 attenuates the effect of the pro-
tumor caveolin-1 in the tumor microenvironment leading to suppression of tumor growth and 
metastasis. With the potential to identify caveolin-1-positive prostate cancers using circulating 
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caveolin-1 as an accessible biomarker, this work establishes a new paradigm for research into 
targeted therapies for personalized cancer treatment.  
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Materials and Methods 
Reagents and antibodies 
Xenolight D-luciferin potassium salt was from Thermo Fisher Scientific (VIC, Australia). Rabbit 
(610059) and mouse anti-caveolin-1 (610407) antibodies were acquired from BD Transduction 
Laboratories (NSW, Australia), anti-β-actin (A1978) and anti-IL-6 (I2143) antibodies from 
Sigma-Aldrich (NSW, Australia), anti-androgen receptor (1852-1) antibodies from Epitomics 
(DKSH, VIC, Australia), antibodies against phospho-Akt (9271), phospho-p44/42 MAPK (9106) 
and Akt (9272) from Cell signaling technology (Genesearch, QLD, Australia), and anti-Erk2 (sc-
154) and anti-human IL-6 (sc-7920) antibodies from Santa cruz biotechnology (Thermo Fisher 
Scientific, VIC, Austrlia). Rabbit anti-cavin-1 antibodies were produced against peptides 
comprising the N-terminal 15 amino acids of human cavin-1 and affinity purified. Anti-human 
Ki-67 (M7240) antibody was purchased from Dako (VIC, Australia) and anti-SMA (CM001C) 
antibody was acquired from Biocare Medical (VIC, Australia). 
Tissue microarray 
Tissue microarrays were obtained from the Australian Prostate Cancer BioResource with human 
ethics approval from the University of Queensland (project number 2008002197). Sections were 
dewaxed and rehydrated through descending graded alcohols to running tap water and then 
washed in 2 changes of phosphate-buffered saline (PBS). Antigen retrieval was performed in 
0.01M Citric acid buffer, pH 6.0 at 105ºC for 15 min using Biocare Decloaking Chamber. After 
washing, endogenous peroxidase activity was blocked by incubating the sections in 3% H2O2 in 
PBS, and the slides were further blocked for 30 min in Biocare Medical Background Sniper 
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(Biocare Medical, CA, USA). Primary antibody incubation was performed overnight at room 
temperature in a humid chamber using the following conditions: rabbit anti-caveolin-1 was 
diluted 1:80 in PBS, rabbit anti-cavin-1 antibodies were diluted 1:50 in Renaissance antibody 
diluent (Biocare Medical, CA, USA). After washing in PBS, horseradish peroxidase (HRP) 
coupled anti-rabbit antibody (Dako Envision Plus, Dako, VIC, Australia) was applied for 30 min. 
Color was developed by application of DAB and H2O2 for 5 min and then excess chromogen was 
removed by washing in running tap water. Sections were lightly counterstained in Mayers’ 
haematoxylin, then dehydrated through ascending graded alcohols, cleared in xylene, and 
mounted. Initial optimization experiments performed using Biocare Medical MACH3 Rabbit 
HRP polymer with caveolin antibody produced excessive background and were disregarded. 
Images were taken using Olympus BX41 microscope using 20x objective in air with PixeLINK 
megapixel firewire 1394 camera. 
Cell lines and stable sublines 
Cervical cancer cell line HeLa, and prostate cancer cell lines PC-3 and LNCaP were purchased 
from American Type Culture Collection (ATCC). Prostate cancer cell line 22Rv1 was a generous 
gift from Dr John Hooper (Mater Medical Research Institute, Brisbane, Australia). HeLa cells 
were maintained in DMEM medium (Invitrogen, VIC, Australia), and all prostate cancer cell 
lines were grown in RPMI-1640 (Invitrogen, VIC, Australia) medium supplemented with 10% 
fetal bovine serum in a humidified atmosphere of 5% CO2 at 37oC. Prostate cancer PC-3 cells 
expressing firefly-luciferase were prepared as previously described in ref 18. To establish stable 
cell lines for cavin-1 expression, Gateway recombination cloning system (Life Technologies) 
was used according to manufacturer’s instructions and as previously carried out by Škalamera et 
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al.48 Human cavin-1 was cloned into the lentivirus plasmid plv411 using forward primer 
5’GGGGACAAGTTTGTACAAAAAAGCAGGCTATGGAGGACCCCACGCTCTATATTGT
CG3’ and reverse primer 5’GGGGACCACTTTGTACAAGAAAGCTGGGTTCAGTCGCTGT 
CGCTCTTGTCC3’ and verified by sequencing. Caveolin-1 plv411 was provided by ARVEC.49 
Lentiviral plv411 constructs were then packaged into lentiviruses for transduction into prostate 
cancer cells. Target cell lines were infected with lentiviruses in the presence of hexadimethrine 
bromide (8 ug/ml), then after 10 days, pure population of stable sublines expressing GFP were 
selected by flow cytometry. 
Immunoblotting 
Total cells were lysed in a buffer containing 20mM Tris pH 7.5, 150 mM NaCl, 0.5% Triton X-
100, 0.5% deoxysodium cholate (DOC), 10 mM sodium fluoride (NaF), 0.5 mM sodium 
vanadate, 1 mM sodium pyrophosphate, 0.5 mM 4-(2-aminoethyl) benzenesulfonyl fluoride 
hydrochloride (AEBSF) and protease inhibitors (1 µg/µL Aprotinin, 1 µg/µL Antipain, 1 µg/µL 
Pepstatin, 1 µg/µL Leupeptin and 2.5 mM Benzamidine). Insoluble material was removed by 
centrifugation at 10,000xg at 4oC for 5 min, and protein concentration was determined using 
BCA assay (Thermo Fisher Scientific, VIC, Australia) following manufacturer’s instructions. 
Total cell lysate (20 µg) was diluted in SDS-PAGE sample buffer and boiled at 96oC for 5 min. 
Proteins were resolved on SDS-PAGE gels and transferred on to PVDF membranes. Membranes 
were blocked with 5% milk powder, and then incubated with primary antibodies; anti-cavin-1 
(1:1,000), anti-caveolin-1 (1:3,000), anti-androgen receptor (1:1,000) and anti-IL-6 (1:1,000) 
overnight at 4oC. Washed membranes were subsequently incubated with horseradish peroxidase-
conjugated secondary antibody (Invitrogen, VIC, Australia) for 1 hr at room temperature, and the 
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signal was detected using SuperSignal West Pico chemiluminescence (Thermo Fisher Scientific, 
VIC, Australia). 
Cell proliferation and anchorage-independent growth assays 
PC-3 and LNCaP sublines were plated at a density of 5 x 104 cells per well, and 1 x 105 cells per 
well of 22Rv1 sublines were plated in 6-well plates. Then, cell proliferation was measured by 
counting cells stained with trypan blue using hemocytometer at day 2, 4, and 6. Anchorage-
independent growth in soft agar was evaluated at day 21 after plating 10,000 cells per well in 6-
well plates between 2 layers of agarose, top layer being 0.35% and bottom layer 0.5%. 
Immunofluorescence 
LNCaP stables were grown on coverslips and fixed in cold methanol. Coverslips were washed 
three times with PBS and incubated with anti-caveolin-1 and anti-cavin-1 followed by their 
appropriate secondary antibodies with PBS washes in between. All antibodies were incubated for 
1 hr. Coverslips were mounted using ProLong Gold (Invitrogen, VIC, Australia), and visualized 
using a Zeiss Meta 510 confocal microscope. 
Orthotopic prostate tumor xenograft study 
The animal experiments described in this study were approved by the University of Queensland 
Animal Ethics Committee (UQDI/326/10/AICR). Seven-week-old male NOD.CB17-Prkdcscid 
(Severe Combined Immunodeficient, Non-Obese Diabetic) mice were purchased from Animal 
Resource Centre (ARC, WA, Australia). Twenty-three mice were randomized into 2 groups, 
control PC-3 (n=11) and PC-3-cavin-1 (n=12). 20 µl cell suspension containing 5 x 105 PC-3 
cells in PBS were orthotopically xenografted into mouse dorsolateral prostate glands under a 
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dissecting microscope. Primary tumor progression was monitored by in vivo whole-body 
bioluminescence. Prior to the imaging, D-luciferin dissolved in PBS was intraperitoneally 
injected, and then the bioluminescence was examined using the IVIS spectrum (Caliper Life 
Sciences, CA, USA). Prostate tumors were collected at the end of the experiment, and tumor 
weight and size were measured. 
All mouse tissues were fixed in 10% buffered formalin for 24 hrs, and then 3 µm Paraffin 
embedded tissue sections were used for immunohistochemistry (IHC). Sections after 
deparaffinization and antigen retrieval were incubated with primary antibodies, including anti-
Ki-67 (1:120 dilutions) and anti-SMA (1:800 dilutions) for 1 hr at room temperature, and anti-
IL-6 (1:50 dilutions) for overnight at 4oC in a humidity chamber. Signals were developed in 
DAB, and sections were lightly counterstained in Mayers’ haematoxylin. Ki-67 positive cells at 
5 arbitrarily selected fields from each tumor were counted at high power field (x400 
magnification) for the quantification of proliferating cells. Semi-quantitative scoring for IL-6 and 
α-SMA was assessed as 0, 1+, 2+, 3+ and 4+, representing nil, weak, moderate, strong and the 
most intense staining, and data are presented as mean ± SEM of five randomly selected 
microscopic fields from each tumor. 
Statistical analysis 
Experimental data were expressed as mean ± SEM and statistical analyses were performed by 
two-tailed Student t-test using GraphPad Prism 5 Software. Significance was considered as p-
value <0.05. 
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Table 1. The expression of caveolin-1 and cavin-1 in normal, non- and malignant prostate 
epithelia 
Caveolin-1 (*p<0.0001) Cavin-1 (p=0.1350) 
Total Negative Positive Total Negative Positive 
Non-cancer Normal 128 123 (96.1%) 5 (3.9%) 141 141 (100.0%) 0 (0.0%) 
BPH 49 45 (91.8%) 4 (8.2%) 50 50 (100.0%) 0 (0.0%) 
Cancer 
Gleason score ≤ 6 66 44 (66.7%) 22 (33.3%) 66 65 (98.5%) 1 (1.5%) 
Gleason score = 7 31 14 (45.2%) 17 (54.8%) 31 30 (96.8%) 1 (3.2%) 
Gleason score ≥ 8 20 5 (25.0%) 15 (75.0%) 20 20 (100.0%) 0 (0.0%) 
Test used: Chi-square test for trend. *Significance < 0.0001. 
Healthy normal specimens were biopsy cores from men with no history of prostate diseases and other cancers. 
Benign prostatic hyperplasia (BPH) specimens were cores from a prostate cancer progression tissue microarray. 
Prostate cancer samples were further classified by Gleason scores: A score of 6 or less; low risk, a score of 7; 
moderate risk, a score of 8 or more; high risk prostate cancer. 
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Table 2. The expression of caveolin-1 and cavin-1 in prostate stroma 
Caveolin-1 (*p<0.0001) Cavin-1 (*P<0.0001) 
Total Negative Positive Total Negative Positive 
Non-cancer Normal 124 0 (0.0%) 124 (100.0%) 133 2 (1.5%) 131 (98.5%) 
BPH 49 1 (2.0%) 48 (98.0%) 49 0 (0.0%) 49 (100.0%) 
Cancer 
Gleason score ≤ 6 65 8 (12.3%) 57 (87.7%) 65 16 (24.6%) 49 (75.4%) 
Gleason score = 7 31 13 (41.9%) 18 (58.1%) 31 9 (29.0%) 22 (71.0%) 
Gleason score ≥ 8 17 6 (35.3%) 11 (64.7%) 17 9 (52.9%) 8 (48.0%) 
Test used: Chi-square test for trend. *Significance < 0.0001. 
Peri-epithelial stroma defined as stroma in 10 cell layers from the epithelia has been examined. Non-cancer normal 
specimens were from men with no prostate diseases, and benign prostatic hyperplasia (BPH) specimens were from a 
prostate cancer progression tissue microarray. Prostate cancer samples were further classified by Gleason scores: A 
score of 6 or less; low risk, a score of 7; moderate risk, a score of 8 or more; high risk prostate cancer. 
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Figure legends 
Figure 1. Immunohistochemistry staining of caveolin-1 and cavin-1 in prostate tissues. (a) 
Representative figures of caveolin-1 immunoreactivity in benign prostatic hyperplasia (BPH) and 
prostate cancer specimens. (b) Representative figures of cavin-1 immunoreactivity in BPH and 
prostate cancer specimens. Endothelial cells of blood vessels (black arrow head) served as an 
internal positive control for caveolin-1 and cavin-1. Bar; 20 μm, x 200. 
Figure 2. Cavin-1 and caveolin-1 expression in prostate cancer cell lines, and effects of cavin-1 
co-expression in caveolin-1 positive prostate cancer PC-3 cells. (a) Expression of caveolin-1 and 
cavin-1 in prostate cancer cell lines. Total cell lysates (20 μg) from HeLa, LNCaP, 22Rv1 and 
PC-3 cells were separated on SDS-PAGE and immunoblotted with cavin-1, caveolin-1 and β-
actin as indicated. Entire lanes showed single bands for the specific reactivity of cavin-1 
antibodies. Representative of at least 3 independent experiments. (b) Growth curve of PC-3 cell 
lines. Cell numbers were determined at the indicated days, and values represent mean ± SEM of 
three independent experiments performed in quadruplicate (* p<0.05). (c) Anchorage-
independent growth assay of PC-3 cell lines. A total of 10,000 cells were seeded in medium with 
soft agar in 6-well plates and cultured at 37oC for 21 days. Experiments were repeated four 
times. 
Figure 3. Effects of cavin-1 co-expression in PC-3 tumor growth and metastasis. (a) 
Representative figures of whole body bioluminescence imaging in NOD/SCID mice. The 
dorsolateral prostate glands of male NOD/SCID mice were injected with 5 x 105 PC-3 cells in 25 
µl PBS, and tumors were imaged at the indicated days. Prior to the imaging, D-luciferin 
dissolved in PBS was intraperitoneally injected. (b) Prostate tumor growth was compared 
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between PC-3 control and PC-3-cavin-1 by the intensity of bioluminescence at the region of 
interest. Six randomly selected mice per group were imaged on the indicated days. At day 42, the 
bioluminescence of every mouse was monitored by the IVIS spectrum. Values represent mean ± 
SEM (* p<0.05). (c) At the end of in vivo experiments, representative PC-3 control and PC-3-
cavin-1 prostate tumors were collected and photographed. (d) Final prostate tumor burden was 
measured six weeks after injecting PC-3 tumor cells (n=11 for PC-3 control and 12 for PC-3-
cavin-1). (e) Ex vivo imaging was performed with lung tissues excised from a subset of mice 
immediately after final in vivo imaging. The mean values of the intensity of bioluminescence in 
the lung tissues were more than 10 times higher in PC-3 control relative to PC-3-cavin-1 group.  
Figure 4. Cavin-1 co-expression affects proliferation and IL-6 expression of tumor cells, and α-
SMA expression of stroma tissues. (a) Immunohistochemical Ki-67 staining of PC-3 control and 
PC-3-cavin-1 tumors for cell proliferation (original magnification, x 200). (b) The number of Ki-
67 positive cells was counted at randomly selected five different fields from each tumor (n=8 per 
group) in high power field.  (c) Representative figures of IL-6 staining in PC-3 control and PC-3-
cavin-1 tumors (x 200). (d) Semiquantitative scoring for IL-6 was assessed at five independent 
microscopic fields for each PC-3 control (n=6) and PC-3-cavin-1(n=6) tumors. (e) 
Immunohistochemical staining of α-SMA in control and cavin-1 group (x 200) (f) α-SMA 
staining was semiquantitatively determined at 5 arbitrarily selected fields from each tumor (n=6 
per group). All data were represented as mean ± SEM with two independent observers. 
Figure 5. Differential effects of caveolin-1 and cavin-1 in prostate cancer 22Rv1 and LNCaP 
cells. (a) Total cell lysates (20 μg) from 22Rv1 and LNCaP stable cell lines expressing caveolin-
1 or cavin-1 were separated on SDS-PAGE and immunoblotted with cavin-1, caveolin-1 and β-
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actin as indicated. (b) Growth curve of stable 22Rv1 cell lines. Cell numbers were determined at 
the indicated days, and values represent mean ± SEM of three independent experiments 
performed in quadruplicates. (c) Growth curve of stable LNCaP cell lines was determined at the 
indicated days by counting cells. (d) Anchorage-independent growth assay of stable 22-Rv1 
cells. A total of 10,000 cells were plated in 6-well plates between 2 layers of agarose, top layer 
being 0.35% and bottom layer 0.5%. Cells were incubated at 37oC for 28 days. (e) Anchorage-
independent growth of stable LNCaP cells was determined by colony formation in soft agar as 
above. LNCaP cells were incubated for 21 days. All Experiments represented in this figure were 
repeated at least four times. 
Figure 6. Cavin-1 co-expression in LNCaP-caveolin-1 cells suppresses anchorage-independent 
growth. (a) Expression level of cavin-1, caveolin-1 and β-actin was measured by 
immunoblotting total cell lysates (20 μg) from LNCaP-caveolin-1 as indicated. (b) Confocal 
immunofluorescence of LNCaP-caveolin-1-cavin-1 cells showing co-localization of caveolin-1 
(red) and cavin-1 (pseudogreen). Bar, 20 µm. The nucleus was visualized with DAPI staining 
(blue).  (c) Growth curve of LNCaP-caveolin-1 cells expressing cavin-1 or control. Cell numbers 
were counted at the indicated days, and values represent mean ± SEM of three independent 
experiments performed in quadruplicates. (d) Anchorage-independent growth assay of LNCaP-
caveolin-1 with or without cavin-1 expression. A total of 10,000 cells were plated in 6-well 
plates between 2 layers of agarose, top layer being 0.35% and bottom layer 0.5%. Cells were 
incubated at 37oC for 21 days. 
Figure 7. Cavin-1 co-expression negatively regulates AR, IL-6 and phospho-Akt. (a) Total cell 
lysates (20 μg) from LNCaP stable cell lines expressing caveolin-1 and/or cavin-1 were 
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separated on SDS-PAGE and immunoblotted with AR and IL-6 as indicated. The relative 
intensity of Western blot signals were quantified using Image J, and the values are represented in 
the bar graph. (b) LNCaP stable cell lines were cultured in serum free media for 24 hr, and then 
conditioned media were collected. Conditioned media (25 μg) and total cell lystaes (5 μg) were 
separated on SDS-PAGE and immunoblotted with IL-6 and caveolin-1 as indicated. Loading 
control; coomassie staining. (c) Western blot analysis shows the decrease of Akt phosphorylation 
by cavin-1 co-expression in LNCaP-caveolin-1 and PC-3 cells. The relative phosphorylation is 
represented in bar graphs. All Experiments represented in this figure were repeated at least three 
times (* p<0.05, ** p<0.005). 
Figure 8. Working model of caveolin-1 and cavin-1 expressions in prostate cancer progression 
and the effect of cavin-1 co-expression in advanced prostate cancer. Normal and non-malignant 
prostate epithelia express neither caveolin-1 nor cavin-1, while normal prostate stroma highly 
expresses both caveolin-1 and cavin-1. Caveolin-1 but not cavin-1 (non-caveolar caveolin-1, 
inset) is up-regulated in prostate cancer as Gleason score increases. On the other hand, stromal 
caveolin-1 and cavin-1 are down-regulated in prostate cancer. Ectopic cavin-1 co-expression 
neutralizes tumor-promoting effects of caveolin-1 microdomains in prostate cancer cells through 
the reduction of IL-6 (cancer cells) and α-smooth muscle actin (α-SMA in stroma). 
 








